Immuneering Corporation (IMRX) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 7 Buy, 4 Hold.
The consensus price target is $12.00, representing an upside of 121.8% from the current price $5.41.
Analysts estimate Earnings Per Share (EPS) of $-1.79 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.04 vs est $-1.79 (missed -13.7%). 2025: actual $-1.27 vs est $-1.42 (beat +10.4%). Analyst accuracy: 88%.
IMRX Stock — 12-Month Price Forecast
$12.00
▲ +121.81% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Immuneering Corporation, the price target is $12.00.
The average price target represents a +121.81% change from the last price of $5.41.
IMRX Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Immuneering Corporation in the past 3 months
EPS Estimates — IMRX
88%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.04
vs Est –$1.79
▼ 12.1% off
2025
Actual –$1.27
vs Est –$1.42
▲ 11.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — IMRX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
